Jazz Pharmaceuticals Announces First Quarter 2014 Financial Results - AZTV7/Cable 13, Me-TV 7.2, HSN 7.3, Phoenix-Prescott, AZ

Jazz Pharmaceuticals Announces First Quarter 2014 Financial Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Jazz Pharmaceuticals plc

Company Reports First Quarter 2014 Total Revenues of $247 Million Driven by Strong Sales of Xyrem, Erwinaze and Defibrotide

Adjusted EPS of $1.61 and GAAP EPS of $(1.58)

DUBLIN, May 8, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter ended March 31, 2014 and reaffirmed and updated financial guidance for 2014.

"We are pleased with the progress made during the first quarter, highlighted by the completion of two transactions that have positioned us well for both near- and long-term growth," said Bruce C. Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals plc. "We initiated the launch of Defitelio in Europe and are making significant progress in advancing late-stage projects in our development portfolio while also delivering continued growth of our key marketed products."

Adjusted net income attributable to Jazz Pharmaceuticals plc for the first quarter of 2014 was $100.8 million, or $1.61 per diluted share, compared to $84.4 million, or $1.37 per diluted share, for the first quarter of 2013.

GAAP net loss attributable to Jazz Pharmaceuticals plc for the first quarter of 2014 was $92.7 million, or $1.58 per diluted share, compared to GAAP net income attributable to Jazz Pharmaceuticals plc of $43.4 million, or $0.71 per diluted share, for the first quarter of 2013. GAAP net loss attributable to Jazz Pharmaceuticals plc for the first quarter of 2014 included an upfront license fee and milestone payment of $127.0 million for JZP-110. Upfront license fees for the first quarter of 2013 were $4.0 million. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included in this press release.

First Quarter 2014 Revenues and Product Sales
Total revenues for the first quarter of 2014 were $246.9 million, an increase of 26% over total revenues of $196.2 million for the first quarter of 2013. This increase was driven primarily by net product sales of Xyrem® (sodium oxybate) oral solution, Erwinaze®/Erwinase® (asparaginase Erwinia chrysanthemi) and defibrotide, marketed under the name Defitelio® (defibrotide) in Europe. Total revenues include net product sales, royalties and contract revenues.

Tables showing actual and pro forma net product sales for the first quarter of 2014 compared to actual and pro forma net product sales for the first quarter of 2013 are included in this press release.

Net product sales for the first quarter of 2014 were as follows:

  • Xyrem: Xyrem net sales increased by 36% to $160.4 million in the first quarter of 2014 compared to $117.5 million in the first quarter of 2013. During the first quarter of 2014, the average number of active Xyrem patients was approximately 11,400.
  • Erwinaze/Erwinase: Erwinaze/Erwinase net sales increased by 12% to $46.9 million in the first quarter of 2014 compared to $41.8 million in the first quarter of 2013. In connection with the EUSA Pharma acquisition in 2012, the company agreed to make a contingent payment of $50.0 million in cash if Erwinaze achieved net sales in the United States of $124.5 million or more in 2013. This net sales milestone was achieved in the fourth quarter of 2013, and, as a result, the company made the contingent payment in the first quarter of 2014.
  • Defitelio/defibrotide: On January 23, 2014, Jazz Pharmaceuticals plc acquired indirect majority control of Gentium S.p.A. Defitelio/defibrotide net sales in the first quarter since the January 23, 2014 closing date of the Gentium acquisition were $12.2 million. Pro forma net sales of Defitelio/defibrotide were $15.1 million in the first quarter of 2014, an increase of 75% compared to pro forma net sales of $8.6 million in the first quarter of 2013. The pro forma information represents net sales of Defitelio/defibrotide as if the Gentium acquisition had closed on January 1, 2013.
  • Prialt® (ziconotide) intrathecal infusion: Net sales of Prialt were $4.3 million in the first quarter of 2014, a decrease of 14% compared to $5.0 million in the first quarter of 2013. The decrease in net sales was due in part to the timing of shipments to the exclusive wholesale distributor and central pharmacy for Prialt.
  • Psychiatry Products: Net sales of the company's psychiatry products were $9.9 million in the first quarter of 2014 compared to $17.7 million in the first quarter of 2013. The decrease was primarily due to the impact of generic competition.
  • Other: Net sales of other products for the first quarter of 2014 were $11.3 million compared to $12.7 million in the first quarter of 2013. On a pro forma basis, net sales of other products for the first quarter of 2014 were $11.7 million compared to $14.1 million in the first quarter of 2013. The pro forma information includes net sales of active pharmaceutical ingredient by Gentium as if the Gentium acquisition had closed on January 1, 2013.

Operating Expenses and Other
Operating expenses for the first quarter of 2014 were $313.6 million compared to $128.1 million for the first quarter of 2013. Operating expenses increased over the prior period primarily due to the following:

  • Cost of product sales for the first quarter of 2014 was $30.9 million on a GAAP basis compared to $27.2 million for the same period in 2013. The increase was primarily due to an increase in acquisition accounting inventory fair value step-up adjustments of $6.5 million, partially offset by lower cost of product sales primarily driven by product mix. Gross margin for the first quarter of 2014, as a percentage of product sales, was 87.4% compared to 86.0% for the same period in 2013.
  • Selling, general and administrative (SG&A) expenses for the first quarter of 2014 were $106.4 million on a GAAP basis compared to $70.5 million for the same period in 2013. The increase was primarily due to an increase in transaction and integration costs and higher headcount and related expenses due to the expansion of the business. Adjusted SG&A expenses for the first quarter of 2014 were $76.5 million, or 31% of total revenues, compared to $56.5 million, or 29% of total revenues, for the same period in 2013.
  • Research and development (R&D) expenses for the first quarter of 2014 were $18.1 million on a GAAP basis compared to $6.7 million for the same period in 2013. Adjusted R&D expenses for the first quarter of 2014 were $15.3 million, or 6% of total revenues, compared to $5.7 million, or 3% of total revenues, for the same period in 2013. The increase in R&D expenses was primarily driven by increased costs associated with the development of the sleep and hematology/oncology product candidates.
  • Acquired in-process research and development expenses for the first quarter of 2014 were $127.0 million on a GAAP basis compared to $4.0 million for the same period in 2013. The increase was due to an upfront license fee and milestone payment of $127.0 million in connection with the acquisition of JZP-110 in January 2014.

Net interest expense for the first quarter of 2014 was $10.1 million compared to $7.4 million for the first quarter of 2013. The increase was due to the company's increased debt levels following the Gentium acquisition in January 2014.

As of March 31, 2014, cash and cash equivalents and short-term investments were $251.4 million and the balance of the company's long-term debt was $1.2 billion. Cash and cash equivalents decreased during the first quarter of 2014 primarily due to funds used by the company to acquire Gentium and JZP-110, offset in part by the net proceeds of new term loans and borrowings under revolving loans.

Recent Developments
During March through early May 2014, the company launched Defitelio commercially in Germany, Austria and the United Kingdom. In April, Defitelio became reimbursable by the Italian National Health System under Law 648. Defitelio is the only treatment approved in the European Union (EU) for severe hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem cell transplantation therapy. Severe VOD is a rare and life-threatening disease.

In April 2014, the company was informed that the Phase 2b data for JZP-110 has been accepted as a late-breaking abstract for oral presentation at SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies, LLC in Minneapolis, Minnesota, U.S.A. on Monday, June 2, 2014.

2014 Financial Guidance

Jazz Pharmaceuticals' 2014 guidance, including updated GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share guidance, is as follows1:


Revenues

$1,100-$1,160 million

Total Net Product Sales

$1,093-$1,153 million

-Xyrem Net Sales

$755-$775 million

-Erwinaze/Erwinase Net Sales

$185-$200 million

-Defitelio/Defibrotide Net Sales

$42-$52 million

Adjusted Gross Margin %2,5

91-92%

Adjusted SG&A Expenses3,5

$315-$325 million

Adjusted R&D Expenses4,5

$55-$65 million

GAAP Net Income Attributable to Jazz Pharmaceuticals plc Per Diluted Share

$1.81-$2.30

Non-GAAP Adjusted Net Income Attributable to Jazz Pharmaceuticals plc Per Diluted Share 5

$8.00-$8.25



1.

2014 guidance includes fair value estimates for the assets acquired and liabilities assumed in the Gentium acquisition and is subject to change if the company obtains additional information during the measurement period (up to one year from the acquisition date).



2.

Excludes $10-$12 million of acquisition accounting inventory fair value step-up adjustments and $3 million in share-based compensation expense from estimated GAAP gross margin of 90-91%.



3.

Excludes $55-$59 million of share-based compensation expense, $25-$30 million of transaction, integration and restructuring costs and $6-$7 million of depreciation expense from estimated GAAP SG&A expenses of $400-$420 million.



4.

Excludes $12-$13 million of share-based compensation expense from estimated GAAP R&D expenses of $67-$78 million.



5.

See "Non-GAAP Financial Measures" below. Reconciliations of non-GAAP adjusted guidance measures are included above and in the tables accompanying this press release.



Conference Call Details
Jazz Pharmaceuticals will host an investor conference call and live audio webcast today at 4:30 p.m. EDT (9:30 p.m. IST) to provide a business and financial update and discuss its 2014 first quarter results. The live webcast may be accessed from the Investors & Media section of the company's website at www.jazzpharmaceuticals.com. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary. Investors may participate in the conference call by dialing +1 866 318 8620 in the U.S., or +1 617 399 5139 outside the U.S., and entering passcode 38923320.

A replay of the conference call will be available through May 15, 2014 by dialing +1 888 286 8010 in the U.S., or +1 617 801 6888 outside the U.S., and entering passcode 77121089. An archived version of the webcast will be available for at least one week in the Investors & Media section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com.

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion, Versacloz™ (clozapine) oral suspension, FazaClo® (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the United States, including Erwinase® and Defitelio® (defibrotide). For more information, please visit www.jazzpharmaceuticals.com.

Non-GAAP Financial Measures
To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the company uses certain non-GAAP (also referred to as "adjusted" or "non-GAAP adjusted") financial measures in this press release and the accompanying tables. The company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company. They are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with the consolidated financial statements prepared in accordance with GAAP. Jazz Pharmaceuticals' management regularly uses these supplemental non-GAAP financial measures internally to understand, manage and evaluate its business and make operating decisions. Compensation of executives is based in part on the performance of the company's business based on certain of these non-GAAP financial measures. In addition, Jazz Pharmaceuticals believes that the presentation of these non-GAAP financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance.

Investors should note that these non-GAAP financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Because of the non-standardized definitions, the non-GAAP financial measures as used by Jazz Pharmaceuticals in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.

As used in this press release, (i) the historical adjusted net income measures attributable to Jazz Pharmaceuticals plc (and the related per share measures) exclude from GAAP net income (loss) attributable to Jazz Pharmaceuticals plc, as applicable, intangible asset amortization, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges, change in fair value of contingent consideration, upfront license fees and milestone payments, depreciation expense and non-cash interest expense; adjust the income tax provision to the estimated amount of taxes that are payable in cash; and adjust for the amount attributable to noncontrolling interests; (ii) the adjusted net income attributable to Jazz Pharmaceuticals plc (and the related per share) guidance measures exclude from estimated GAAP net income attributable to Jazz Pharmaceuticals plc intangible asset amortization and depreciation expense, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction, integration and restructuring costs, upfront license fees and milestone payments and non-cash interest expense; adjust the income tax provision to the estimated amount of taxes that are payable in cash; and adjust for the amount attributable to noncontrolling interests; (iii) the adjusted gross margin percentage guidance excludes from estimated GAAP gross margin percentage acquisition accounting inventory fair value step-up adjustments and share-based compensation expense; (iv) the adjusted SG&A expenses guidance excludes from estimated GAAP SG&A expenses share-based compensation expense, transaction, integration and restructuring costs and depreciation expense; and (v) the adjusted R&D expenses guidance excludes from estimated GAAP R&D expenses share-based compensation expense.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements, including, but not limited to, statements related to Jazz Pharmaceuticals' future financial results, including 2014 financial guidance, the potential to advance late stage projects in our development portfolio, the expectation of continued growth of our key marketed products and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition or other sodium oxybate products that compete with Xyrem and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Defitelio; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment, in particular the need to obtain appropriate pricing and reimbursement approvals in order to launch Defitelio in certain European countries representing a significant market opportunity for Defitelio; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on single source suppliers, including the risk that the company may not be able to obtain and supply sufficient product to meet commercial demand or to meet requirements for clinical trial supplies; the difficulty and uncertainty of pharmaceutical product development, including the timing thereof, the uncertainty of clinical success, such as the risk that results from early clinical trials may not be predictive of results obtained in later and larger clinical trials planned or anticipated to be conducted for the company's product candidates, and the uncertainty of regulatory approval; risks associated with business combination or product acquisition transactions, such as the risk that the acquired businesses, including the acquired Gentium business, will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Annual Report on Form 10-K for the year ended December 31, 2013 and future filings and reports by the company, including the company's Form 10-Q for the quarter ended March 31, 2014. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.



JAZZ PHARMACEUTICALS PLC

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)



Three Months Ended
March 31,


2014



2013

Revenues:




Product sales, net

$

244,986



$

194,652

Royalties and contract revenues

1,933



1,585

Total revenues

246,919



196,237

Operating expenses:




Cost of product sales (excluding amortization of acquired developed technologies)

30,924



27,220

Selling, general and administrative

106,363



70,528

Research and development

18,109



6,747

Acquired in-process research and development

127,000



4,000

Intangible asset amortization

31,182



19,555

Total operating expenses

313,578



128,050

Income (loss) from operations

(66,659)



68,187

Interest expense, net

(10,076)



(7,399)

Foreign currency gain

123



271

Income (loss) before income tax provision

(76,612)



61,059

Income tax provision

17,027



17,634

Net income (loss)

(93,639)



43,425

Net loss attributable to noncontrolling interests, net of tax

(989)



-

Net income (loss) attributable to Jazz Pharmaceuticals plc

$

(92,650)



$

43,425





Net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc:




Basic

$

(1.58)



$

0.74

Diluted

$

(1.58)



$

0.71

Weighted-average ordinary shares used in calculating net income (loss) per ordinary share attributable to Jazz Pharmaceuticals plc:




Basic

58,526



58,358

Diluted

58,526



61,511



JAZZ PHARMACEUTICALS PLC

SUMMARY OF PRODUCT SALES, NET

(In thousands)

(Unaudited)



Three Months Ended

March 31,


2014



2013

Xyrem

$

160,378



$

117,526

Erwinaze/Erwinase

46,920



41,816

Defitelio/defibrotide

12,209



-

Prialt

4,309



4,986

Psychiatry

9,866



17,650

Other

11,304



12,674

Total net product sales

$

244,986



$

194,652



The following unaudited pro forma information represents the net product sales for the three months ended March 31, 2014 and 2013, respectively, as if the Gentium acquisition had been completed on January 1, 2013:


SUMMARY OF PRODUCT SALES, NET (PRO FORMA)

(In thousands)

(Unaudited)



Three Months Ended

March 31,


2014



2013

Xyrem

$

160,378



$

117,526

Erwinaze/Erwinase

46,920



41,816

Defitelio/defibrotide

15,106



8,610

Prialt

4,309



4,986

Psychiatry

9,866



17,650

Other

11,710



14,068

Total pro forma net product sales

$

248,289



$

204,656



JAZZ PHARMACEUTICALS PLC

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)



March 31,

2014



December 31,

2013

ASSETS




Current assets:




Cash and cash equivalents

$

245,874



$

636,504

Investments

5,502



-

Accounts receivable, net of allowances

154,986



124,805

Inventories

36,988



28,669

Prepaid expenses

14,335



7,183

Deferred tax assets, net

35,888



33,613

Other current assets

23,747



33,843

Total current assets

517,320



864,617

Property and equipment, net

30,048



14,246

Intangible assets, net

1,755,861



812,396

Goodwill

763,763



450,456

Deferred tax assets, net, non-current

94,250



74,597

Deferred financing costs

25,896



14,605

Other non-current assets

9,296



7,304

Total assets

$

3,196,434



$

2,238,221

LIABILITIES AND SHAREHOLDERS' EQUITY




Current liabilities:




Accounts payable

$

72,538



$

21,005

Accrued liabilities

147,737



119,718

Current portion of long-term debt

9,513



5,572

Income taxes payable

824



336

Contingent consideration

-



50,000

Deferred tax liability, net

6,259



6,259

Deferred revenue

1,138



1,138

Total current liabilities

238,009



204,028

Deferred revenue, non-current

5,433



5,718

Long-term debt, less current portion

1,189,096



544,404

Deferred tax liability, net, non-current

471,993



168,497

Other non-current liabilities

25,395



20,040

Total Jazz Pharmaceuticals plc shareholders' equity

1,248,893



1,295,534

Noncontrolling interests

17,615



-

Total liabilities and shareholders' equity

$

3,196,434



$

2,238,221



JAZZ PHARMACEUTICALS PLC

RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

(In thousands, except per share amounts)

(Unaudited)



Three Months Ended

March 31,


2014



2013

GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc

$

(92,650)



$

43,425

Intangible asset amortization

31,182



19,555

Share-based compensation expense

13,815



8,757

Acquisition accounting inventory fair value step-up adjustments

8,022



1,545

Transaction and integration costs

17,733



1,022

Restructuring charges

-



949

Change in fair value of contingent consideration

-



4,500

Upfront license fees and milestone payments

127,000



4,000

Depreciation

1,309



575

Non-cash interest expense

1,638



1,229

Income tax adjustments

(5,944)



(1,132)

Adjustments for amount attributable to noncontrolling interests

(1,258)



-

Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc

$

100,847



$

84,425





GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc per diluted share

$

(1.58)



$

0.71

Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share

$

1.61



$

1.37

Shares used in computing GAAP reported net income (loss) attributable to Jazz Pharmaceuticals plc per diluted share amounts

58,526



61,511

Shares used in computing non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share amounts

62,517



61,511



JAZZ PHARMACEUTICALS PLC

RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS AND OTHER INFORMATION

(In thousands, except per share amounts and percentages)

(Unaudited)



Three Months Ended


March 31, 2014


March 31, 2013


GAAP Reported



Adjustments



Non-GAAP Adjusted *



GAAP Reported



Adjustments



Non-GAAP Adjusted *

Total revenues

$

246,919



$

-



$

246,919



$

196,237



$

-



$

196,237

Cost of product sales

30,924



(8,208)


(a)

22,716



27,220



(2,296)


(a)

24,924

Selling, general and administrative

106,363



(29,890)


(b)

76,473



70,528



(13,988)


(b)

56,540

Research and development

18,109



(2,781)


(c)

15,328



6,747



(1,064)


(c)

5,683

Acquired in-process research and development

127,000



(127,000)



-



4,000



(4,000)



-

Intangible asset amortization

31,182



(31,182)



-



19,555



(19,555)



-

Interest expense, net

10,076



(1,638)


(d)

8,438



7,399



(1,229)


(d)

6,170

Foreign currency gain

123



-



123



271



-



271

Income (loss) before income tax provision

(76,612)



200,699


(e)

124,087



61,059



42,132


(e)

103,191

Income tax provision

17,027



5,944


(f)

22,971



17,634



1,132


(f)

18,766

Effective tax rate (g)

N/A


(h)



18.5%



28.9%





18.2%

Net income (loss)

(93,639)



194,755


(i)


101,116



43,425



41,000


(i)

84,425

Net income (loss) attributable to noncontrolling interests, net of tax

(989)



1,258


(j)

269



-



-


(j)

-

Net income (loss) attributable to Jazz Pharmaceuticals plc

$

(92,650)


$

193,497


(k)

$

100,847



$

43,425



$

41,000


(k)

$

84,425













Net income (loss) attributable to Jazz Pharmaceuticals plc per diluted share

$

(1.58)





$

1.61



$

0.71





$

1.37



JAZZ PHARMACEUTICALS PLC

RECONCILIATIONS OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS AND OTHER INFORMATION

(In thousands)

(Unaudited)

* Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc and its line item components and related non-GAAP adjusted financial measures shown in the tables above are not meant to be considered in isolation or as a substitute for comparable GAAP reported measures, and should be read in conjunction with the condensed consolidated financial statements prepared in accordance with GAAP. The company believes that each of these non-GAAP adjusted financial measures is helpful in understanding its past financial performance and potential future results, particularly in light of the effect of various acquisition and divestiture transactions effected by the company. In addition, the company believes that the presentation of these non-GAAP adjusted financial measures is useful to investors because it enhances the ability of investors to compare its results from period to period and allows for greater transparency with respect to key financial metrics the company uses in making operating decisions, and also because the company's investors and analysts regularly use them to model and track the company's financial performance. Specifically, the company believes that each of these non-GAAP adjusted financial measures provides useful information to management, investors and analysts by excluding, as applicable, intangible asset amortization, share-based compensation expense, acquisition accounting inventory fair value step-up adjustments, transaction and integration costs, restructuring charges, change in fair value of contingent consideration, upfront license fees and milestone payments, depreciation expense and non-cash interest expense that may not be indicative of the company's core operating results and business outlook, and by including adjustments to convert the income tax provision to the estimated amount of taxes that are payable in cash and adjustments for the amount attributable to noncontrolling interests. Investors should note that these non-GAAP adjusted financial measures are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the company's results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP adjusted financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its non-GAAP adjusted financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP adjusted financial measures. Because of the non-standardized definitions, the non-GAAP adjusted financial measures appearing in the tables above may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the company's competitors and other companies.


Explanation of Adjustments and Certain Line Items:



(a)

Acquisition accounting inventory fair value step-up adjustments of $8,022 and $1,545, share-based compensation expense of $181 and $709, depreciation expense of $5 and $0, and restructuring charges of $0 and $42 for the three months ended March 31, 2014 and 2013, respectively.



(b)

Transaction and integration costs of $17,599 and $1,022, share-based compensation expense of $11,175 and $7,005, depreciation expense of $1,116 and $554, change in fair value of contingent consideration of $0 and $4,500 and restructuring charges of $0 and $907 for the three months ended March 31, 2014 and 2013, respectively.



(c)

Share-based compensation expense of $2,459 and $1,043, depreciation expense of $188 and $21 and transaction and integration costs of $134 and $0 for the three months ended March 31, 2014 and 2013, respectively.



(d)

Non-cash interest expense associated with debt discount and debt issuance costs for the respective three-month period.



(e)

Sum of adjustments (a) through (d) plus the adjustments for acquired in-process research and development and intangible asset amortization for the respective three-month period.



(f)

Adjustments to convert the income tax provision to the estimated amount of taxes payable in cash for the respective three-month period.



(g)

Income tax provision divided by income before income tax provision for the respective three-month period (for the three months ended March 31, 2014, on a non-GAAP adjusted basis only).



(h)

The GAAP effective tax rate for the three months ended March 31, 2014 is not meaningful because there was a loss before income tax provision during the period. After adjusting the loss before income tax provision by excluding an upfront fee and milestone payment of $127,000 for JZP-110, we would have had income before income tax provision of $50,388, resulting in an effective tax rate of 33.8% for the three months ended March 31, 2014 based on the income tax provision of $17,027, compared to 28.9% for the same period in 2013. This increase was primarily due to a higher level of profits subject to U.S. federal and state income taxes in the 2014 period, and higher losses in other jurisdictions where no tax benefit is available in the year.



(i)

Net of adjustments (e) and (f) for the respective three-month period.



(j)

Adjustments for amount attributable to noncontrolling interests for the respective three-month period.



(k)

Net of adjustments (i) and (j) for the respective three-month period.



JAZZ PHARMACEUTICALS PLC

RECONCILIATION OF GAAP TO NON-GAAP ADJUSTED 2014 GUIDANCE

(In millions, except per share amounts)

(Unaudited)



GAAP net income attributable to Jazz Pharmaceuticals plc

$113 - $144

Intangible asset amortization and depreciation

133 - 139

Share-based compensation expense

70 - 75

Acquisition accounting inventory fair value step-up

10 - 12

Transaction, integration and restructuring costs

25 - 30

Upfront license fees and milestone payments

127

Non-cash interest expense

7

Income tax adjustments

(5) - 5

Adjustments for amount attributable to noncontrolling interests

(2) - (1)

Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc

$496 - $520



GAAP net income attributable to Jazz Pharmaceuticals plc per diluted share

$1.81 - $2.30

Non-GAAP adjusted net income attributable to Jazz Pharmaceuticals plc per diluted share

$8.00 - $8.25



Weighted-average ordinary shares used in per share computations

62 - 63



©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and AZ-TV. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.